- Home
- INTR vs AKRO Comparison
INTR vs AKRO Comparison
Compare INTR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | AKRO |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | INTR | AKRO |
|---|---|---|
| Price | $8.64 | $54.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $7.78 | ★ $73.56 |
| AVG Volume (30 Days) | 2.4M | ★ 2.4M |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 51.09 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $1,056,044,206.00 | N/A |
| Revenue This Year | $83.08 | N/A |
| Revenue Next Year | $23.65 | N/A |
| P/E Ratio | $16.34 | ★ N/A |
| Revenue Growth | ★ 34.63 | N/A |
| 52 Week Low | $3.88 | $21.34 |
| 52 Week High | $10.22 | $58.40 |
Technical Indicators
Market Signals| Indicator | INTR | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 68.63 |
| Support Level | $8.18 | $54.30 |
| Resistance Level | $8.56 | $54.70 |
| Average True Range (ATR) | 0.34 | 0.17 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 48.30 | 71.07 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.